Biotech | May 12, 2022
Mawi DNA Technologies launches NextSWAB for Covid-19 test results
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
UCB plans to submit regulatory applications in Q3 2022
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Subscribe To Our Newsletter & Stay Updated
